<DOC>
	<DOCNO>NCT00664144</DOCNO>
	<brief_summary>The primary objective evaluate efficacy rasburicase term prevention treatment hyperuricemia relate Tumor Lysis Syndrome ( TLS ) 2 population adult patient , previously treat urate oxidase , relapse aggressive non-Hodgkin 's lymphoma ( NHL ) risk TLS , present hyperuricemia and/or bulky disease diagnostic relapse . The secondary objective : - evaluate efficacy rasburicase term renal protection , - evaluate safety rasburicase two cohort patient , - correlate efficacy safety result antibody generation/level .</brief_summary>
	<brief_title>Rasburicase Treatment/Prevention Hyperuricemia Adult Patients With Relapsing Aggressive Non Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>Patients histologically proven aggressive Non Hodgkin 's Lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>